Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "1"

Research

Emerging issues in the Pacific Basin

This review provides a snapshot of some key environmental health issues that will provide ongoing challenges for the Pacific Basin region in the coming decades

Research

Hypoglycemia alarm enhancement using data fusion

The acceptance of closed-loop blood glucose (BG) control using continuous glucose monitoring systems (CGMS) is likely to improve.

Research Project Coordinator TETO Project

Research Project Coordinator, Health Promotion & Education Research

News & Events

The Kids Research Institute Australia welcomes world-leading new laws for vapes

The Kids Research Institute Australia welcomes the Federal Government's stringent vaping reforms that took effect on 1 July 2024.

Research

“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials

Each year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.

Research

Acute Lymphoblastic Leukemia in Infants: A Distinctive, High-Risk Subtype of Childhood Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) in infants younger than 1 year of age is an aggressive, high-risk subtype of childhood ALL. Infant ALL with KMT2A-r is characteristically poorly responsive to chemotherapy and hematopoietic stem cell transplantation. New strategies, such as molecularly targeted therapies and immunotherapies, are in development and show promise in preclinical models and early phase studies.

Research

Interferon β-1a ring prophylaxis to reduce household transmission of SARS-CoV-2: a cluster randomised clinical trial

Accumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity. Our objective was to examine the prophylactic potential of IFN administration to limit viral transmission.

Research

Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia

KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.

RESP-ACT

The aim of RESP-ACT is to reduce these children’s respiratory hospital admissions and visits to Emergency Department, and to help them and their families to have as the best possible quality of life.